The transcription factor LMO2 is a robust marker of vascular endothelium and vascular neoplasms and selected other entities

Dita Gratzinger, Shuchun Zhao, Robert West, Robert V. Rouse, Hannes Vogel, Elena Cubedo Gil, Ronald Levy, Izidore S. Lossos, Yasodha Natkunam

Research output: Contribution to journalArticle

23 Scopus citations

Abstract

The transcription factor LMO2 is involved in vascular and hematopoietic development and hematolymphoid neoplasia. We have demonstrated that LMO2 is expressed nearly ubiquitously in native and neoplastic vasculature, including lymphatics. LMO2 reactivity is otherwise virtually absent in nonhematolymphoid tissues except in breast myoepithelium, prostatic basal cells, and secretory phase endometrial glands. Vasculature is LMO2- in adult and fetal heart, brain of older adults, hepatic sinusoids, and hepatocellular carcinoma. LMO2 is uniformly expressed in benign vascular and lymphatic neoplasms and in most malignant vascular neoplasms with the exception of epithelioid vascular neoplasms of pleura and bone. Among nonvascular neoplasms, LMO2 reactivity is present in giant cell tumor of tendon sheath, juvenile xanthogranuloma, a subset of gastrointestinal stromal tumors, small round blue cell tumors, and myoepithelial-derived neoplasms. The restricted expression pattern, nuclear localization, and crisp staining of LMO2 in paraffin blocks make it an attractive candidate for the diagnostic immunohistochemistry laboratory.

Original languageEnglish (US)
Pages (from-to)264-278
Number of pages15
JournalAmerican journal of clinical pathology
Volume131
Issue number2
DOIs
StatePublished - Feb 1 2009

    Fingerprint

Keywords

  • Angiosarcoma
  • Endothelium
  • Gastrointestinal stromal tumor
  • Giant cell tumor of tendon sheath
  • LMO2
  • Myoepithelial

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this